Progressive supranuclear palsy: Advances in diagnosis and management

Parkinsonism Relat Disord. 2020 Apr:73:105-116. doi: 10.1016/j.parkreldis.2020.04.014. Epub 2020 May 25.


Progressive supranuclear palsy (PSP) is a complex clinicopathologic disease with no current cure or disease modulating therapies that can only be definitively confirmed at autopsy. Growing understanding of the phenotypic diversity of PSP has led to expanded clinical criteria and new insights into etiopathogenesis that coupled with improved in vivo biomarkers makes increased access to current clinical trials possible. Current standard-of-care treatment of PSP is multidisciplinary, supportive and symptomatic, and several trials of potentially disease modulating agents have already been completed with disappointing results. Current ongoing clinical trials target the abnormal aggregation of tau through a variety of mechanisms including immunotherapy and gene therapy offer a more direct method of treatment. Here we review PSP clinicopathologic correlations, in vivo biomarkers including MRI, PET, and CSF biomarkers. We additionally review current pharmacologic and non-pharmacologic methods of treatment, prior and ongoing clinical trials in PSP. Newly expanded clinical criteria and improved specific biomarkers will aid in identifying patients with PSP earlier and more accurately and expand access to these potentially beneficial clinical trials.

Keywords: Gene therapy; Immunotherapy; Progressive supranuclear palsy; Tauopathy; Treatment.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Drug Therapy*
  • Genetic Therapy*
  • Humans
  • Immunotherapy*
  • Supranuclear Palsy, Progressive / diagnosis*
  • Supranuclear Palsy, Progressive / etiology
  • Supranuclear Palsy, Progressive / therapy*